Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial

Mats Christian Højbjerg Lassen, John W. Ostrominski, Silvio E. Inzucchi, Brian L. Claggett, Ian Kulac, Pardeep Jhund, Rudolf A. de Boer, Adrian F. Hernandez, Mikhail N. Kosiborod, Carolyn S.P. Lam, Felipe A. Martinez, Sanjiv J. Shah, Akshay S. Desai, Magnus Petersson, Anna Maria Langkilde, Kieran F. Docherty, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan*

*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)
5 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: A pre-specified analysis of the DELIVER trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science